A technical guide to hard-to-synthesize peptides—what makes a sequence difficult in solid-phase peptide synthesis (SPPS), what problems you’ll see in crude material, and how synthesis teams typically mitigate risk.
Difficult peptide synthesis describes sequences that resist routine solid-phase peptide synthesis (SPPS) and require targeted optimization to meet purity, yield, or reproducibility targets. Difficulty is usually driven by sequence behavior—aggregation, secondary structure, steric effects, or labile motifs—rather than length alone.
Expert signal: in practice, most synthesis failures trace back to on-resin aggregation and reduced chain mobility, which silently lowers coupling efficiency and amplifies deletion/truncation impurities.
Hydrophobic stretches (e.g., Leu/Ile/Val/Phe-rich) tend to aggregate on-resin, lowering effective coupling efficiency.
Certain patterns promote backbone hydrogen bonding and β-sheet formation, “locking” the chain and limiting reagent access.
Small inefficiencies accumulate over many coupling steps, increasing the probability of truncations and complex crude profiles.
Multiple cysteines introduce disulfide pairing complexity and folding heterogeneity even when the linear chain is correct.
Proline and sterically hindered residues can slow coupling kinetics; repeated prolines and constrained motifs are common risk points.
Certain sequence contexts can favor side reactions (e.g., aspartimide pathways in Asp-X regions), complicating purification.
If you share the sequence and the observed issue (e.g., deletion series, low solubility, split peaks), the synthesis strategy can be targeted to the dominant failure mode instead of trial-and-error.
Example: A 35–40 amino acid peptide enriched in Leu/Ile/Val with two internal cysteines may synthesize poorly despite repeated recoupling. On-resin aggregation reduces coupling efficiency, while post-cleavage the peptide shows poor aqueous solubility and multiple HPLC peaks.
Typical fix: Reduce resin loading, introduce backbone-disrupting building blocks in the hydrophobic region, and plan controlled disulfide oxidation. In some cases, fragment synthesis provides a cleaner and more reproducible path.
Figure: Common mechanism in difficult peptide synthesis — on-resin aggregation restricts reagent access, leading to blocked coupling and deletion sequences (n-1, n-2) observed in crude material.
This table is designed for fast troubleshooting. Match what you see in crude/HPLC to the most likely root cause and the usual mitigation levers.
If you share your sequence plus what you observe (deletion series, split peaks, insolubility), optimization can be targeted instead of trial-and-error.
For difficult peptides, the goal is to achieve an application-appropriate specification with a robust path: predictable coupling, manageable crude profile, and a purification/folding plan that scales.
Send a sequence for review Read FAQ
A peptide is considered difficult when standard SPPS workflows repeatedly fail to meet purity, yield, or reproducibility targets without targeted optimization, such as aggregation control, backbone disruption, or fragment-based synthesis.
Not always. Length increases cumulative risk, but many short peptides are difficult if they are highly hydrophobic, β-sheet-prone, or cysteine-rich.
Deletion series typically indicate incomplete couplings at one or more steps. Aggregation and steric hindrance are common root causes, and mitigation often focuses on the specific failing region.
This can occur due to conformers, partial folding, disulfide heterogeneity, or aggregation-driven chromatographic behavior. Strategy may include folding control or purification condition tuning.
Yes, but they often require sequence-specific synthesis adjustments and a solubility/purification plan (solvents, gradients, salt form) to prevent precipitation and improve recovery.
Fragment approaches are commonly considered for long peptides and sequences where stepwise SPPS repeatedly fails to reach spec despite targeted optimization.
Send the sequence (1-letter code), length, modifications, quantity, and purity target. If you have analytics (HPLC/MS), include what you observed (e.g., deletion series, split peaks, insolubility). We’ll recommend a practical strategy.
Trusted by biotech leaders worldwide for over 40+ years of delivering high quality, fast and scalable synthetic biology solutions.